The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II, open-label, randomized clinical trial of panitumumab plus gemcitabine and oxaliplatin (GEMOX) versus GEMOX alone as first-line treatment in advanced biliary tract cancer: The Vecti-BIL study.
 
Francesco Leone
No Relationships to Disclose
 
Donatella Marino
No Relationships to Disclose
 
Roberto Filippi
No Relationships to Disclose
 
Stefano Cereda
No Relationships to Disclose
 
Carmen Belli
No Relationships to Disclose
 
Rosella Spadi
No Relationships to Disclose
 
Guglielmo Nasti
No Relationships to Disclose
 
Massimo Montano
No Relationships to Disclose
 
Alessio Amatu
No Relationships to Disclose
 
Giuseppe Aprile
No Relationships to Disclose
 
Celeste Cagnazzo
No Relationships to Disclose
 
Gianpiero Fasola
No Relationships to Disclose
 
Salvatore Siena
Stock and Other Ownership Interests - Ignyta
Honoraria - Amgen; Bayer
Consulting or Advisory Role - Amgen; Bayer; Ignyta; Roche/Genentech; Sanofi
Speakers' Bureau - Amgen; Bayer
Research Funding - Bayer (Inst)
Patents, Royalties, Other Intellectual Property - Amgen
Travel, Accommodations, Expenses - Amgen; Bayer; Roche
 
Libero Ciuffreda
No Relationships to Disclose
 
Michele Reni
Consulting or Advisory Role - Boehringer Ingelheim; Celgene; Genentech
Research Funding - Celgene (Inst)
 
Massimo Aglietta
No Relationships to Disclose